The purpose of this session will be to review management strategies of common sleep complaints, examine newer literature in the arena and apply the guidance to clinical pharmacy practice. Insomnia continues to be a common health issue for older adults with the patient population being extremely prone to medication related problems. Obstructive sleep apnea (OSA) and restless leg syndrome (RLS) can both be complicating factors for a patient's insomnia and excessive daytime sleepiness. New guidelines published on RLS management now recommend alpha2-delta calcium channel ligands over dopamine agonists for first line treatment of chronic RLS. OSA continues to be a contributor to underlying chronic disease states such as hypertension and is frequently under documented on a patient's problem list. Attendees will leave empowered to tackle this potential nightmare in practice through evidence-based approaches. The BCACP/BCGP Clinical Sessions are part of the professional development program for the recertification of board-certified ambulatory care pharmacists and/or geriatric pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCACP and/or BCGP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCACP/BCGP Clinical Sessions posttests will be available on December 14, 2022, at www.accp.com/myaccount to anyone who has purchased access to the BCACP and/or BCGP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 18, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 12, 2023.